Comparison between low-dose simvastatin and cholestyramine in moderately severe hypercholesterolemia

In a 6-week multicenter study, we compared the efficacy and tolerance of a treatment with 10 mg of simvastatin, a new inhibitor of the HMG-CoA reductase to that of 12 g cholestyramine in 145 patients whose total cholesterol remained between 250 and 350 mg/dl after 4 weeks of a standard lipid-lowering diet. Simvastatin at the dosage of 10 mg appeared to be at least as efficient as 12 g of cholestyramine and generally better tolerated